サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1159172

3-ホスホイノシチド依存性プロテインキナーゼ1の世界市場（2022年～2028年）

3 Phosphoinositide Dependent Protein Kinase 1 Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 110 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.65円
3-ホスホイノシチド依存性プロテインキナーゼ1の世界市場（2022年～2028年）
出版日: 2022年09月20日
発行: Orion Market Research
ページ情報: 英文 110 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の3-ホスホイノシチド依存性プロテインキナーゼ1の市場規模は、予測期間中に大幅なCAGRで成長すると予想されています。世界中で乳がんが増加していることは、市場拡大の主な要因となっています。

当レポートでは、世界の3-ホスホイノシチド依存性プロテインキナーゼ1市場について調査分析し、市場概要、競合情勢、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • 主要戦略分析
  • COVID-19が主要企業に与える影響

第4章 市場セグメンテーション

  • 世界の3-ホスホイノシチド依存性プロテインキナーゼ1市場：薬剤タイプ別
    • HCI-1708
    • AR-12
    • PHT-427
    • SNS-229
    • その他
  • 世界の3-ホスホイノシチド依存性プロテインキナーゼ1市場：用途別
    • 病院
    • クリニック
    • その他

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他アジア太平洋
  • 世界のその他の地域

第6章 企業プロファイル

  • Arno Therapeutics Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Sunesis Pharmaceuticals Inc.
  • Tolero Pharmaceuticals Inc.
図表

LIST OF TABLES

  • 1. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL HCI-1708 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL AR-12 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL PHT-427 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL SNS-229 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL OTHERS 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 8. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
  • 14. NORTH AMERICAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 15. EUROPEAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. EUROPEAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
  • 17. EUROPEAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
  • 20. ASIA-PACIFIC 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

 

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET, 2021-2028 (%)
  • 4. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY DRUG TYPE, 2021 VS 2027 (%)
  • 5. GLOBAL HCI-1708 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL AR-12 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL PHT-427 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL SNS-229 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL OTHERS 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 11. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN HOSPITALS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN OTHERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. US 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. CANADA 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. UK 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. FRANCE 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. GERMANY 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. ITALY 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. SPAIN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF EUROPE 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. INDIA 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CHINA 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. JAPAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. REST OF THE ASIA-PACIFIC 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF THE WORLD 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2025893

Global 3 Phosphoinositide Dependent Protein Kinase 1 Market Size, Share, and Trends Analysis Report by Drug Type (HCI-1708, AR-12, PHT-427, SNS 229, and Others), and by Application (Hospitals, Clinics, and Others) Forecast Period (2022-2028)

The global 3 phosphoinositide dependent protein kinase 1 market is anticipated to grow at a significant CAGR during the forecast period. 3 phosphoinositide dependent kinase 1, also known as PDK1, is a member of the AGC protein kinase family that is involved in a range of cellular processes, including the activation of the PI3K signaling pathway, which has been linked to the start and progression of various human malignancies. The rising prevalence of breast cancer throughout the world is a primary reason driving the market's expansion. According to the World Health Organization (WHO), 2.3 million women were diagnosed with breast cancer in 2020, with 685 000 deaths globally. Breast cancer has been diagnosed in 7.8 million women in the previous five years as of the end of 2020, making it the most common disease in the world.

The global 3 phosphoinositide dependent protein kinase 1 market is segmented based on drug type and application. Based on the drug type, the market is sub-segmented into HCI-1708, AR-12, PHT-427, SNS 229, and others. Based on the application, the market is sub-segment into hospitals, clinics, and others.

The global 3 phosphoinositide dependent protein kinase 1 market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. Among these regions, the Asia-Pacific region is expected to grow at a significant CAGR over the forecast period. Breast cancer is much more common in countries in sub-Saharan Africa and Southeast Asia than in the US. In many of these countries including India, Australia, and others, it is the most common type of cancer among the population. According to the Cancer Council of Australia, in 2020, around 150,000 new cases of cancer and 50,000 deaths were reported due to cancer across the country.

The major companies serving the global 3 phosphoinositide dependent protein kinase 1 market include Boehringer Ingelheim GmbH, AstraZeneca PLC, Arno Therapeutics Inc., Sanofi SA, Novartis International AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2020, Merck & Co. Inc. and VelosBio Inc. entered into a definitive agreement. As per the agreement, the Merck acquired all the outstanding shares of VelosBio for $2.75 billion in cash. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1).

Research Methodology

The market study of the global 3 phosphoinositide dependent protein kinase 1 market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. We have worked on different approaches to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalogue.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global 3 Phosphoinositide Dependent Protein Kinase 1 Market Research and Analysis by Drug Type.

2. Global 3 Phosphoinositide Dependent Protein Kinase 1 Market Research and Analysis by Application.

The Report Covers:

  • Comprehensive Research Methodology of the global 3 phosphoinositide dependent protein kinase 1 market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global 3 phosphoinositide dependent protein kinase 1 market.
  • Insights about market determinants that are stimulating the global 3 phosphoinositide dependent protein kinase 1 market.
  • The regional distribution of forecasted revenues with detailed and extensive market segments.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global 3 Phosphoinositide Dependent Protein Kinase 1 Market
  • Recovery Scenario of Global 3 Phosphoinositide Dependent Protein Kinase 1 Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global 3 Phosphoinositide Dependent Protein Kinase 1 Market by Drug Type
    • 4.1.1. HCI-1708
    • 4.1.2. AR-12
    • 4.1.3. PHT-427
    • 4.1.4. SNS-229
    • 4.1.5. Others
  • 4.2. Global 3 Phosphoinositide Dependent Protein Kinase 1 Market by Application
    • 4.2.1. Hospitals
    • 4.2.2. Clinics
    • 4.2.3. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Arno Therapeutics Inc.
  • 6.2. AstraZeneca PLC
  • 6.3. Bayer AG
  • 6.4. Boehringer Ingelheim GmbH
  • 6.5. Novartis International AG
  • 6.6. Pfizer Inc.
  • 6.7. Sanofi SA
  • 6.8. Sunesis Pharmaceuticals Inc.
  • 6.9. Tolero Pharmaceuticals Inc.